Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation
Transfusion · 2024
DOI: 10.1111/trf.17909 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transfusion, 2024. Verfasst von Moazzam Shahzad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Filgrastim, Hematopoietic Stem Cell Mobilization, Biosimilar Pharmaceuticals, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 19 Literaturangaben.
Themen: Mobilisation
Abstract (Originalsprache)
Background
Nivestym, a biosimilar granulocyte colony‐stimulating factor (G‐CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization of peripheral blood stem cells (PBSC) in allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We aim to compare the efficacy of Nivestym and Neupogen for PBSC mobilization in healthy allogeneic donors.
Methods
We conducted a retrospective single‐center study including 541 adult allo‐HSCT donors receiving Nivestym (January 2013–July 2020), or Neupogen (July 2020–June 2023) for donor PBSC mobilization. Bivariate analysis was conducted using SPSS version 28. Statistical significance was determined at a p ‐value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
- H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
- Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.
ORCID-Profile: Muhammad Kashif Amin, Muhammad Umair Mushtaq
Zitieren
APA
Shahzad, M., Amin, M. K., Bellman, P., Al-Ramahi, J., Noor, J., Vyas, A., Mahmoudjafari, Z., McGuirk, M., DeJarnette, S., Ahmed, N., Abdallah, A. O., Shune, L., Singh, A. K., McGuirk, J. P., Abhyankar, S., & Mushtaq, M. U. (2024). Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation. Transfusion. https://doi.org/10.1111/trf.17909
Vancouver
Shahzad M, Amin MK, Bellman P, Al-Ramahi J, Noor J, Vyas A, et al. Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation. Transfusion. 2024. doi:10.1111/trf.17909
BibTeX
@article{Shahzad2024,
author = {Shahzad, Moazzam and Amin, Muhammad Kashif and Bellman, Polina and Al-Ramahi, Joe and Noor, Jawad and Vyas, Abhinav and Mahmoudjafari, Zahra and McGuirk, Matthew and DeJarnette, Shaun and Ahmed, Nausheen and Abdallah, Al-Ola and Shune, Leyla and Singh, Anurag K and McGuirk, Joseph P and Abhyankar, Sunil and Mushtaq, Muhammad Umair},
title = {Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17909}
}
EUVIMED